Compare Quest Diagnostics Inc (DGX) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs JPMorgan Chase & Co — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while JPMorgan Chase & Co trades at $343.5 (market cap $911.47B). The key difference: JPMorgan Chase & Co is far larger — about 40× Quest Diagnostics Inc's market cap, and JPMorgan Chase & Co pays the higher dividend (1.75%). Which is the better fit depends on your goals.
| DGX | JPM | |
|---|---|---|
Market Cap | $22.80B | $911.47B |
Sector | Health | Financials |
52-Week High | $216.02 | $342.89 |
52-Week Low | $166.42 | $282.84 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | 1.75% |
Volume | — | 10,479,943 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
JPMorgan Chase (JPM) trades at $334.53, down 0.58% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 and Q2 2026 earnings beats, with Q1 EPS of $5.94 versus $5.47 expected and Q2 EPS of $7.7 versus $5.59 expected, though Q4 2025 missed expectations. Revenue grew to $181.85B in 2025, with a net income margin of 31.61% and ROE of 17.03%. Analyst consensus is a Moderate Buy with a $369.67 price target, and recent news highlights CEO Jamie Dimon's economic warnings and upcoming bank earnings focus.
JPMorgan's outlook remains positive driven by earnings momentum and solid profitability, but risks include geopolitical tensions, cybersecurity threats from AI, and macroeconomic volatility cited by management. The stock offers potential upside to the consensus target, supported by institutional buying interest, though investors should weigh elevated debt levels and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
